Ovid Therapeutics
OVID
83 hedge funds and large institutions have $64.5M invested in Ovid Therapeutics in 2020 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 40 increasing their positions, 14 reducing their positions, and 23 closing their positions.
186% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 14
3.85% more ownership
Funds ownership: 39.66% → 43.51% (+3.9%)
9% less funds holding
Funds holding: 91 → 83 (-8)
35% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 23
55% less capital invested
Capital invested by funds: $144M → $64.5M (-$79.6M)
71% less call options, than puts
Call options by funds: $205K | Put options by funds: $703K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.19M |
| 2 |
Renaissance Technologies
New York
|
+$3.31M |
| 3 |
BlackRock
New York
|
+$3.04M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.81M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$6.3M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.57M |
| 4 |
AC
AWH Capital
Dallas,
Texas
|
-$1.29M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$695K |
OVID Hedge Fund Activity: Q4 2020 in Review
83 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q4 2020, worth a combined $64.5M — down 55% from $144M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of OVID and 15 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 40 added.
The largest buyer was BVF Inc, adding an estimated $4.19M. The largest seller was Fidelity Investments, exiting entirely with an estimated $9.81M sold.
- 83 institutional investors held Ovid Therapeutics (OVID) as of Q4 2020, down from 91 in Q3 2020.
- Funds reported $64.5M of Ovid Therapeutics stock for Q4 2020, down 55% quarter-over-quarter.
- 15 funds opened new Ovid Therapeutics positions in Q4 2020 and 23 closed out, a net change of -8 holders.
- The largest Ovid Therapeutics buyer in Q4 2020 was BVF Inc, an estimated $4.19M added.
- The largest Ovid Therapeutics seller in Q4 2020 was Fidelity Investments, an estimated $9.81M sold.
Based on aggregated 13F filings for Q4 2020.